You are here

Study Evaluating Sirolimus in the Treatment of Kidney Transplant

Last updated on August 9, 2018

FOR MORE INFORMATION
Study Location
Albacete, , 2006 Spain
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Kidney Failure, Kidney Diseases
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0+
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Renal transplantation

- Biopsy-confirmed chronic rejection

- Treatment with mofetil mycophenolate among cyclosporine or tacrolimus

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Transplant of any organ other than the kidney

- Current important infection

- Acute rejection within 12 weeks prior to inclusion

NCT00282217
Pfizer
Completed
Study Evaluating Sirolimus in the Treatment of Kidney Transplant

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Dermatitis, Atopic Dermatitis, Eczema, Skin Diseases, Genetic Skin Diseases, Inborn Genetic Diseases, Eczematous Skin Diseases, Hypersensitivity, Immediate Hypersensitivity, Immune System Diseases
NCT03627767
All Genders
12+
Years
Multiple Sites
Diabetes Mellitus, Type 2 Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Diseases
NCT01301456
Females
18+
Years
Multiple Sites
Tuberculosis, Non-tuberculous Mycobacterial Diseases (Including MAC Disease)
NCT00810407
All Genders
Study Evaluating Sirolimus in the Treatment of Kidney Transplant
Sirolimus in the Treatment of Histological Defined Chronic Allograft Nephropathy
The aim of this study is to test whether withdrawal of calcineurin inhibitors, followed by treatment with sirolimus, may improve renal function in renal transplant recipients with chronic allograft nephropathy.
Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Kidney Failure
  • Kidney Diseases
Drug: Sirolimus
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
Not Provided
Not Provided

Inclusion Criteria:

  • Renal transplantation
  • Biopsy-confirmed chronic rejection
  • Treatment with mofetil mycophenolate among cyclosporine or tacrolimus

Exclusion Criteria:

  • Transplant of any organ other than the kidney
  • Current important infection
  • Acute rejection within 12 weeks prior to inclusion
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
 
NCT00282217
101467
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Trial Manager For Spain, [email protected]
Wyeth is now a wholly owned subsidiary of Pfizer
March 2007

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now